Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Alzheimer disease is a devastating chronic disease without adequate therapy. More than 10 years ago, it was demonstrated in transgenic mouse models that vaccination may be a novel, disease-modifying therapy for Alzheimer. Subsequent clinical development has been a roller-coaster with some positive and many negative news. Here, we would like to summarize evidence that next generation vaccines optimized for old people and focusing on patients with mild disease stand a good chance to proof efficacious for the treatment of Alzheimer.

Original publication

DOI

10.4161/hv.28183

Type

Journal article

Journal

Hum Vaccin Immunother

Publication Date

2014

Volume

10

Pages

847 - 851

Keywords

Abeta, Alzheimer, antibody, third generation, vaccine, Alzheimer Disease, Alzheimer Vaccines, Animals, Disease Models, Animal, Drug Discovery, Humans, Mice, Transgenic, Treatment Outcome, Vaccination